Challenges and opportunities in targeting the menin-MLL interaction.

Menin is an essential co-factor of oncogenic MLL fusion proteins and the menin-MLL interaction is critical for development of acute leukemia in vivo. Targeting the menin-MLL interaction with small molecules represents an attractive strategy to develop new anticancer agents. Recent developments, including determination of menin crystal structure and development of potent small molecule and peptidomimetic inhibitors, demonstrate the feasibility of targeting the menin-MLL interaction. On the other hand, biochemical and structural studies revealed that MLL binds to menin in a complex bivalent mode engaging two MLL motifs, and therefore inhibition of this protein-protein interaction represents a challenge. This review summarizes the most recent achievements in targeting the menin-MLL interaction as well as discusses potential benefits of blocking menin in cancer.

[1]  Yutaka Suzuki,et al.  STAT6-mediated displacement of polycomb by trithorax complex establishes long-term maintenance of GATA3 expression in T helper type 2 cells , 2010, The Journal of experimental medicine.

[2]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Detection of disordered regions in globular proteins using 13C‐detected NMR , 2012, Protein science : a publication of the Protein Society.

[4]  R. Slany.  The molecular biology of mixed lineage leukemia , 2009, Haematologica.

[5]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[6]  Jie Liang,et al.  CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues , 2006, Nucleic Acids Res..

[7]  F. Collins,et al.  Menin Interacts with the AP1 Transcription Factor JunD and Represses JunD-Activated Transcription , 1999, Cell.

[8]  R. Thakker.  Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) , 2014, Molecular and Cellular Endocrinology.

[9]  X. Hua,et al.  In search of tumor suppressing functions of menin , 2007, Molecular and Cellular Endocrinology.

[10]  J. Hess,et al.  MLL associates specifically with a subset of transcriptionally active target genes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Manfred Kansy,et al.  Fluorine Interactions at the Thrombin Active Site: Protein Backbone Fragments HCαCO Comprise a Favorable CF Environment and Interactions of CF with Electrophiles , 2004, Chembiochem : a European journal of chemical biology.

[12]  Jun O. Liu,et al.  Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. , 2003, Cancer research.

[13]  M. Cosgrove,et al.  Mixed lineage leukemia: a structure–function perspective of the MLL1 protein , 2010, The FEBS journal.

[14]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[15]  J. Hsieh,et al.  MLL fusions: Pathways to leukemia , 2009, Cancer biology & therapy.

[16]  S. Mandal,et al.  Histone Methylase MLL1 plays critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo , 2012, Oncogene.

[17]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[18]  Sean Davis,et al.  Genome-Wide Analysis of Menin Binding Provides Insights into MEN1 Tumorigenesis , 2006, PLoS genetics.

[19]  Jolanta Grembecka,et al.  Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction , 2010, The Journal of Biological Chemistry.

[20]  Raja Jothi,et al.  Genome-Wide Characterization of Menin-Dependent H3K4me3 Reveals a Specific Role for Menin in the Regulation of Genes Implicated in MEN1-Like Tumors , 2012, PloS one.

[21]  O. Rozenblatt-Rosen,et al.  Phosphorylation of the Menin Tumor Suppressor Protein on Serine 543 and Serine 583 , 2006, Molecular Cancer Research.

[22]  Ya-Xiong Chen,et al.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Han Liu,et al.  HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. , 2013, The Journal of clinical investigation.

[24]  Hui Zhang,et al.  MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. , 2010, Cancer cell.

[25]  N. Ohkura,et al.  Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms , 2011, Cancer science.

[26]  Andrew D Westwell,et al.  Protein–protein interactions as targets for small-molecule therapeutics in cancer , 2008, Expert Reviews in Molecular Medicine.

[27]  H. Imachi,et al.  Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells , 2011, Journal of endocrinological investigation.

[28]  R. Slany,et al.  When epigenetics kills: MLL fusion proteins in leukemia , 2005, Hematological oncology.

[29]  F. Collins,et al.  The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. , 2001, Oncogene.

[30]  L. Hunyady,et al.  Menin dynamics and functional insight: Take your partners , 2010, Molecular and Cellular Endocrinology.

[31]  E. Bruford,et al.  Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases , 2012, Clinical genetics.

[32]  K. Mulder,et al.  Menin links estrogen receptor activation to histone H3K4 trimethylation. , 2006, Cancer research.

[33]  T. Ishida,et al.  Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance , 2010, Breast Cancer Research and Treatment.

[34]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[35]  S. Mandal,et al.  Mixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo , 2012, British Journal of Cancer.

[36]  C. Pui,et al.  Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region , 2002, The Lancet.

[37]  J. Licht,et al.  HOX deregulation in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[38]  C. Edwards,et al.  Clinical studies of multiple endocrine neoplasia type 1 (MEN1) , 1996, QJM : monthly journal of the Association of Physicians.

[39]  R. Thakker.  Multiple endocrine neoplasia type 1 , 2012, Indian journal of endocrinology and metabolism.

[40]  G. Kay,et al.  Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. , 2004, Molecular cell.

[41]  A. Shilatifard.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. , 2012, Annual review of biochemistry.

[42]  Z. Yin,et al.  Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription , 2013, Proceedings of the National Academy of Sciences.

[43]  S. Korsmeyer,et al.  Altered Hox expression and segmental identity in Mll-mutant mice , 1995, Nature.

[44]  J. Ho,et al.  A tumorigenic MLL-homeobox network in human glioblastoma stem cells. , 2013, Cancer research.

[45]  G. Hendy,et al.  Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Zhao-Qi Wang,et al.  Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. , 2003, Molecular endocrinology.

[47]  F. Collins,et al.  The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation , 2001, Oncogene.

[48]  F. Collins,et al.  Menin, the product of the MEN1 gene, is a nuclear protein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[50]  P. Bédard,et al.  Menin: the protein behind the MEN1 syndrome. , 2009, Advances in experimental medicine and biology.

[51]  A. F. Stewart,et al.  Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development , 2006, Development.

[52]  N. Zeleznik-Le,et al.  MLL: How complex does it get? , 2005, Journal of cellular biochemistry.

[53]  Thomas A Milne,et al.  Interaction of MLL amino terminal sequences with menin is required for transformation. , 2005, Cancer research.

[54]  Arndt Borkhardt,et al.  Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization , 2004, Molecular and Cellular Biology.

[55]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[56]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[57]  X. Hua,et al.  Menin: a scaffold protein that controls gene expression and cell signaling. , 2013, Trends in biochemical sciences.

[58]  S. Mandal,et al.  Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle , 2009, The FEBS journal.

[59]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene , 2008, Human mutation.

[60]  Thomas A Milne,et al.  Regulation of MLL1 H3K4 methyltransferase activity by its core components , 2006, Nature Structural &Molecular Biology.

[61]  A. D’Andrea,et al.  Menin associates with FANCD2, a protein involved in repair of DNA damage. , 2003, Cancer research.

[62]  Jason E. Gestwicki,et al.  Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity , 2012, Expert Reviews in Molecular Medicine.

[63]  F. Collins,et al.  The 32-Kilodalton Subunit of Replication Protein A Interacts with Menin, the Product of the MEN1 Tumor Suppressor Gene , 2003, Molecular and Cellular Biology.

[64]  B. Owens,et al.  HOX and Non‐HOX Homeobox Genes in Leukemic Hematopoiesis , 2002, Stem cells.

[65]  H. Masai,et al.  Functional Interaction between Tumor Suppressor Menin and Activator of S-Phase Kinase , 2004, Cancer Research.

[66]  B. Boehm,et al.  Primary structure, gene expression and chromosomal mapping of rodent homologs of the MEN1 tumor suppressor gene. , 1999, Biochimica et biophysica acta.

[67]  Liu Liu,et al.  Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. , 2013, Journal of medicinal chemistry.

[68]  A. H. Smits,et al.  Quantitative Dissection and Stoichiometry Determination of the Human SET1/MLL Histone Methyltransferase Complexes , 2013, Molecular and Cellular Biology.

[69]  R. D. Hanson,et al.  MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. D. Boer,et al.  The MLL recombinome of acute leukemias , 2006, Leukemia.

[71]  O. Rozenblatt-Rosen,et al.  Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Natarajan Ganesan,et al.  Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon , 2010, Cancer Cell International.

[73]  Zijie Feng,et al.  SUMO modification of menin. , 2013, American journal of cancer research.

[74]  Thomas A. Milne,et al.  Physical Association and Coordinate Function of the H3 K4 Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF , 2005, Cell.

[75]  S. Marx.  Molecular genetics of multiple endocrine neoplasia types 1 and 2 , 2005, Nature Reviews Cancer.

[76]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[77]  M. Meyerson,et al.  Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. , 2013, Blood.

[78]  Maho Takahashi,et al.  Menin Missense Mutants Associated with Multiple Endocrine Neoplasia Type 1 Are Rapidly Degraded via the Ubiquitin-Proteasome Pathway , 2004, Molecular and Cellular Biology.

[79]  R. Humphries,et al.  Hox genes in hematopoiesis and leukemogenesis , 2007, Oncogene.

[80]  J. Hess,et al.  Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia , 2008, International journal of hematology.

[81]  M. Lei,et al.  The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.

[82]  A. Sloan,et al.  Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential , 2011, Cell Death and Differentiation.

[83]  J. Rowley,et al.  International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy‐related myelodysplastic syndromes and acute leukemia: Overview report , 2002, Genes, chromosomes & cancer.

[84]  F. Collins,et al.  A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Hess,et al.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. , 2005, Cancer research.

[86]  A. F. Stewart,et al.  Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. , 2007, Molecular biology of the cell.

[87]  T. Cierpicki,et al.  Crystal Structure of Menin Reveals Binding Site for Mixed Lineage Leukemia (MLL) Protein* , 2011, The Journal of Biological Chemistry.

[88]  M. Meyerson,et al.  The Menin Tumor Suppressor Protein Is Phosphorylated in Response to DNA Damage , 2011, PloS one.

[89]  Maksymilian Chruszcz,et al.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.

[90]  S. Mandal,et al.  Overexpression of human histone methylase MLL1 upon exposure to a food contaminant mycotoxin, deoxynivalenol , 2009, The FEBS journal.

[91]  S. Chin,et al.  MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines , 1999, Oncogene.

[92]  C. Allis,et al.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.

[93]  Richard A Young,et al.  Global and Hox-specific roles for the MLL1 methyltransferase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.